Body Diffusion Weighted Imaging (DWI) - IVIM

QUIBIM

QUIBIM has developed a noninvasive post-processing application designed to calculate the water molecules diffusivity in tissues, allowing to detect fast water molecules diffusivity from slow water molecules diffusivity. This module calculates IVIM MRI biomarkers (Intra-Voxel Incoherent Motions) by applying the bi-exponential modeling of the diffusion signal with the use of two different b-values. IVIM is an advanced diffusion method that allows the quantification of Diffusion (D), Perfusion (D*) and Vascular Fraction (f) of the tissues.
Product specifications Information source: Vendor
Last updated: March 10, 2020
General
Product name Body Diffusion Weighted Imaging (DWI) - IVIM
Company QUIBIM
Subspeciality Abdomen, Breast
Modality MR
Disease targeted solid tumors, prostate cancer, rectal cancer and breast cancer, glioblastoma, multiple myeloma, aggressive lymphoma
Key-features Parametric maps, Diffusion coefficient, Psuedodiffusion coefficient, Perfusion fraction
Suggested use During: interactive decision support (shows abnormalities/results only on demand), report suggestion, Need to draw ROI
Data characteristics
Population Follow-up of tumoral staging and treatment response
Input MR DWI (DIffusion Weighted Imaging) with multiple b-values
Input format
Output One-page structured report: parametric maps, histograms and statistics summary of the diffusion coefficient, pseudodiffusion coefficient, perfusion fraction.
Output format DICOM Secondary Capture / PDF
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically after drawing ROI
Processing time 1 - 10 minutes
Certification
CE Certified, Class IIa
FDA No or not yet
Market presence
On market since 01-2019
Distribution channels
Countries present (clinical, non-research use) 10
Paying clinical customers (institutes) 5+
Research/test users (institutes) 15+
Pricing
Pricing model License
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers Martí-Bonmatí L, Ramírez-Fuentes C, Alberich-Bayarri Á, Ruiz-Llorca C. State-of-the-art of bone marrow imaging in multiple myeloma. Curr Opin Oncol. 2015 Nov; 27(6): 540-50.